At a glance

ClinicalIndex Comparison Record

Phase 2Unknown· 57 target

Drug / intervention

Thymosin a1 +2 moredrug

Likely dose

Thymosin a1 1.6mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03663764

NCT03663764Phase 2Unknown

Compare CT.gov

Hypofractionated Radiotherapy Combined With Concurrent Weekly Chemotherapy and Thymosin α1 in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-arm Phase II Study

Sun Yat-sen University·interventional·Posted Sep 10, 2018·Updated Dec 10, 2021

In Brief

A Phase 2 clinical trial evaluating Thymosin a1, hypofractionated radiotherapy, and 1 other intervention for Thymoma and Thymic Carcinoma. Targeting 57 participants across 1 site.

Detailed Summary

This phase II study was to assess the efficacy and toxicity of hypofractionated radiotherapy (HRT) combined with weekly docetaxel/platinum and thymosin α1 in patients with unresectable or recurrent thymic epithelia tumors (TETs).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsThymoma and Thymic Carcinoma

CountriesChina

Collaborators--

Timeline

Phase 2UnknownOverdue

20192020202120222023202420252026

Enrollment StartAug 2018

First PostedSep 2018

Primary CompletionAug 2023

TodayJul 2026

First PostedSep 10, 2018

Enrollment StartAug 13, 2018

Primary CompletionAug 1, 2023

TodayJul 1, 2026

Enrollment to primary: 5.0 yearsPosted 7.8 years ago

Interventions

Thymosin a1drug

All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.

hypofractionated radiotherapyradiation

HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.

concurrent chemoradiotherapydrug

All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .